SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-08-05
👔
Akari Therapeutics Plc
@AKTX_InsiderForm 4 Filing: Farag Kameel D. Acquires (Grant) $12,995 of $AKTX
STOCK AWARD / GRANT
⚡ MATERIALITY: 3/10
corporate issuer
Akari Therapeutics Plc
Ticker: $AKTX
Transaction Value
$12,995
Price/Share: $11.50
transaction date
2026-07-16
Shares: 1,130
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Farag Kameel D., holds the title of Interim CFO at Akari Therapeutics Plc.
On 2026-07-16, the insider transacted 1,130 shares.The shares were transacted at a weighted average price of $11.50 per share, resulting in a total market-relevant value of $12,995.
Executive Summary Summary
Farag Kameel D. (Interim CFO) was granted $13K of $AKTX
Post-Transaction Position: 21,581 shares
SEC Accession No: 0001493152-26-036231 (CIK: 2093620)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.